Novartis Now Expects To Grow Sales At +5% CAGR 2024-2029

NOVARTIS AG NOVN:

• UPGRADES MID-TERM GUIDANCE AND HIGHLIGHTS DEEP PIPELINE IN CORE THERAPEUTIC AREAS TO DRIVE LONG-TERM GROWTH

• MID-TERM SALES GUIDANCE UPGRADED TO +6% CAGR 2023-2028 AND +5% 2024-2029

• STRONG MOMENTUM IN BUSINESS WITH 8 IN-MARKET BRANDS WITH USD 3BN+ TO USD 8BN+ PEAK SALES POTENTIAL AND 15+ NEAR-TERM SUBMISSION-ENABLING READOUTS

• REMAINS ON TRACK TO DELIVER CORE OPERATING INCOME MARGIN(1) OF 40%+ BY 2027

• NOVARTIS AG - IDENTIFIED MORE THAN 30 ASSETS IN PIPELINE WITH SIGNIFICANT POTENTIAL TO REJUVENATE OUR PORTFOLIO AND SUPPORT MID-SINGLE-DIGIT GROWTH POST 2029